[go: up one dir, main page]

NO20054389L - Cycloalkyl-substituted alkanoic acid derivatives, process for preparation and use thereof as a drug - Google Patents

Cycloalkyl-substituted alkanoic acid derivatives, process for preparation and use thereof as a drug

Info

Publication number
NO20054389L
NO20054389L NO20054389A NO20054389A NO20054389L NO 20054389 L NO20054389 L NO 20054389L NO 20054389 A NO20054389 A NO 20054389A NO 20054389 A NO20054389 A NO 20054389A NO 20054389 L NO20054389 L NO 20054389L
Authority
NO
Norway
Prior art keywords
preparation
acid derivatives
alkanoic acid
cycloalkyl
substituted alkanoic
Prior art date
Application number
NO20054389A
Other languages
Norwegian (no)
Other versions
NO20054389D0 (en
Inventor
Heiner Glombik
Eugen Falk
Hans-Ludwig Schaefer
Stefanie Keil
Dirk Gretzke
Christian Stapper
Jochen Goerlitzer
Wolfgang Wendler
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20054389D0 publication Critical patent/NO20054389D0/en
Publication of NO20054389L publication Critical patent/NO20054389L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/10—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Det beskrives arylsykloalkyl substituerte alkansyrederivater og fysiologisk godtagbare salter og fysiologisk funksjonelle derivater derav. Det beskrives forbindelser med formel I, der restene har de angitte betydninger, samt deres fysiologisk godtagbare salter og også fremgangsmåter for deres fremstilling. Forbindelsene egner seg for behandling og/eller prevensjon av forstyrrelser av fettsyrestoffskifte og forstyrrelser i glukoseutnyttelse samt forstyrrelser der insulinresistens spiller en rolle.Arylic cycloalkyl substituted alkanoic acid derivatives and physiologically acceptable salts and physiologically functional derivatives thereof are disclosed. Compounds of formula I are described in which the residues have the meanings indicated, as well as their physiologically acceptable salts and also methods for their preparation. The compounds are suitable for the treatment and / or prevention of fatty acid metabolic disorders and glucose utilization disorders as well as disorders where insulin resistance plays a role.

NO20054389A 2003-02-27 2005-09-22 Cycloalkyl-substituted alkanoic acid derivatives, process for preparation and use thereof as a drug NO20054389L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10308356A DE10308356A1 (en) 2003-02-27 2003-02-27 Cycloalkyl substituted alkanoic acid derivatives, process for their preparation and their use as medicaments
PCT/EP2004/001587 WO2004076401A1 (en) 2003-02-27 2004-02-19 Cycloalkyl-substituted alkanoic acid derivatives, methods for the production thereof, and use thereof as a medicament

Publications (2)

Publication Number Publication Date
NO20054389D0 NO20054389D0 (en) 2005-09-22
NO20054389L true NO20054389L (en) 2005-11-03

Family

ID=32841933

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054389A NO20054389L (en) 2003-02-27 2005-09-22 Cycloalkyl-substituted alkanoic acid derivatives, process for preparation and use thereof as a drug

Country Status (22)

Country Link
EP (1) EP1599443B1 (en)
JP (1) JP2006519200A (en)
KR (1) KR20050115255A (en)
CN (1) CN100469761C (en)
AR (1) AR043431A1 (en)
AT (1) ATE538086T1 (en)
BR (1) BRPI0407871A (en)
CA (1) CA2516633A1 (en)
CO (1) CO5690544A2 (en)
DE (1) DE10308356A1 (en)
HR (1) HRP20050739A2 (en)
IL (1) IL170315A (en)
MA (1) MA27743A1 (en)
MX (1) MXPA05008990A (en)
NO (1) NO20054389L (en)
PA (1) PA8596701A1 (en)
PE (1) PE20040958A1 (en)
PL (1) PL377755A1 (en)
RU (1) RU2005129998A (en)
TW (1) TW200505830A (en)
WO (1) WO2004076401A1 (en)
ZA (1) ZA200505766B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
JP2007511467A (en) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド Dipeptidyl peptidase inhibitor
MXPA06001601A (en) 2003-08-13 2006-08-25 Takeda Pharmaceutical 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors.
SI1942898T2 (en) 2005-09-14 2014-08-29 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
BRPI0617207A2 (en) 2005-09-29 2011-07-19 Sanofi Aventis phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and use as pharmaceuticals
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
KR20250030215A (en) 2023-08-24 2025-03-05 도레이첨단소재 주식회사 System for recyclying discharge water

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61716B1 (en) * 1987-06-02 1994-11-30 Warner Lambert Co Antihyperlipidemic and antiatherosclerotic urea compounds
US5420164A (en) * 1991-04-04 1995-05-30 Yoshitomi Pharmaceutical Industries, Ltd. Cycloalkylurea compounds
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6057338A (en) * 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
JP3727536B2 (en) * 1997-08-22 2005-12-14 エフ．ホフマン−ラ ロシュ アーゲー N-alkanoylphenylalanine derivatives
WO1999022735A1 (en) * 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
JP2002201171A (en) * 2000-10-27 2002-07-16 Toa Eiyo Ltd Ureacarboxylic acid derivatives
JP2002201127A (en) * 2000-12-28 2002-07-16 Pola Chem Ind Inc Urea derivative
WO2002064130A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds

Also Published As

Publication number Publication date
CA2516633A1 (en) 2004-09-10
MA27743A1 (en) 2006-02-01
DE10308356A1 (en) 2004-09-09
AU2004215678A1 (en) 2004-09-10
CN1753865A (en) 2006-03-29
IL170315A (en) 2010-11-30
WO2004076401A1 (en) 2004-09-10
MXPA05008990A (en) 2005-10-18
CN100469761C (en) 2009-03-18
TW200505830A (en) 2005-02-16
PA8596701A1 (en) 2004-09-16
NO20054389D0 (en) 2005-09-22
EP1599443B1 (en) 2011-12-21
ATE538086T1 (en) 2012-01-15
JP2006519200A (en) 2006-08-24
ZA200505766B (en) 2006-05-31
KR20050115255A (en) 2005-12-07
BRPI0407871A (en) 2006-03-01
RU2005129998A (en) 2006-03-20
HRP20050739A2 (en) 2006-08-31
EP1599443A1 (en) 2005-11-30
PE20040958A1 (en) 2005-02-01
PL377755A1 (en) 2006-02-20
AR043431A1 (en) 2005-07-27
CO5690544A2 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
NO20081367L (en) Phenyl and pyridyl-1,2,4-oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
NO20085064L (en) 4,5-diphenyl-pyrimidinyl-oxy or mercapto-substituted carboxylic acids, processes for their preparation and use thereof as medicaments
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
NO20085066L (en) 4,5-diphenyl-pyrimidinyl-amino-substituted carboxylic acids, process for their preparation and use thereof as medicaments
PE20050255A1 (en) NEW CYANTIAZOLIDES AND PROCEDURE FOR THEIR PREPARATION AS MEDICINES
MX2009003958A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof.
NO20085068L (en) Phenylamino-benzoxazole-substituted carboxylic acids, process for their preparation and use thereof as medicaments
NO20081369L (en) Phenyl and pyridinyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
WO2012165914A3 (en) Novel diphenylmethane derivatives as sglt2 inhibitors
NO20071577L (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory diseases
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HK1202448A1 (en) Topical formulation for administering a compound
WO2006099941A8 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
CY1109370T1 (en) Oxadiazolone derivatives as PPAR delta agonists
MXPA05008993A (en) Diarylcycloalkyl derivatives, method for their production and their use as medicaments.
NO20054408L (en) 3 (2-Phenyl-oxazol-4-yl-methoxy) -cyclohexylmethoxyacetic acid derivatives and similar compounds as PPAR modulators for the treatment of type 2 diabetes and arteriosclerosis
MX2009006913A (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome.
NO20081681L (en) N- [1,3,4] -thiadiazol-2-yl-benzenesulfonamides, process for their preparation and their use as pharmaceuticals
NO20054389L (en) Cycloalkyl-substituted alkanoic acid derivatives, process for preparation and use thereof as a drug
NO20064951L (en) 1,3,4-oxadiazole-2-ones as PPAR delta modulators and their use
WO2006021000A3 (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i epsilon
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
NO20054381L (en) 1,3-substituted cycloalkyl derivatives with acidic, usually heterocyclic groups, their preparation and their use as a drug
NO20065073L (en) New beta agonists, methods of their preparation and their use as drugs.
NO20040811L (en) Diarylcycloalkyl derivatives, process for their preparation and their use as PPAR activators.